Eylea Drives Regeneron To Profit
Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) first quarter 2012 earnings (excluding special items but including stock-based compensation) of 15 cents per share compared favorably with the Zacks Consensus Estimate of a net loss of 24 cents and the year-ago loss of 49 cents. Higher revenues boosted earnings in the quarter. Total revenue in the reported quarter soared [...]
Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) first quarter 2012 earnings (excluding special items but including stock-based compensation) of 15 cents per share compared favorably with the Zacks Consensus Estimate of a net loss of 24 cents and the year-ago loss of 49 cents. Higher revenues boosted earnings in the quarter.
Total revenue in the reported quarter soared 107% to $232.0 million driven by strong sales of eye-drug Eylea. This was the first full quarter of the drug in the market. The drug, … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards